Faced with a growing incidence of drug-resistant infections and threats by the government to reduce or eliminate Medicare payments for hospital-acquired conditions, US hospitals are redoubling their efforts to contain nosocomial infections. One possibility that may become standard practice in the future is screening patients prior to hospital admission to see if they are carriers of common, resistant microorganisms. However, to be practical, this will require an inexpensive, rapid test that can easily be performed at the point of care, an advance that has not yet reached clinical reality.
There are a number of emerging companies that have identified this opportunity and are working on various accelerated testing platforms, ranging from molecular diagnostics to chromogenic media-based tests—all with the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?